芙露饮对频发感染患儿免疫力提升的疗效研究

Efficacy of enhancing immunity of Fuluyin for children with frequent infections

目的探究芙露饮对频发呼吸道感染的患儿治疗效果及免疫力影响。方法选取2012年6月至2013年7月于本院就诊的反复呼吸道感染的患儿108例,依据分层随机分组法将患者分为治疗组及对照组,每组各54例;对照组给予常规抗感染等方法进行治疗;治疗组患儿在对照组治疗方案基础上加用口服芙露饮进行治疗,观察比较两组患儿治疗疗效、反复呼吸道感染的预防效果以及药物不良反应情况。结果治疗前两组患儿的免疫球蛋白G(Ig G)、免疫球蛋白A(Ig A)、免疫球蛋白M(Ig M)、C-反应蛋白(CRP)及血细胞沉降速率(ESR)比较差异均无统计学意义(P均>0.05);治疗1周后治疗组患儿的CRP、ESR及体温均显著低于对照组,差异具有统计学意义(P均<0.05);治疗2个月后治疗组患儿Ig G为(10.42±3.87)g/L、Ig A为(1.96±0.78)g/L及Ig M为(1.15±0.57)g/L,分别显著高于对照组的(8.13±3.46)g/L、(1.27±0.53)g/L和(0.82±0.46)g/L,差异均具有统计学意义(P均<0.05);治疗期间治疗组患者出现寒战及喘息例数显著低于对照组,差异有统计学意义(P均<0.05);治疗期间两组患儿出现头痛、恶心、腹泻及皮疹等不良反应的例数比较差异无统计学意义(P均>0.05)。结论应用芙露饮辅助反复呼吸道感染患儿的治疗,可明显提高感染控制效果,提高患儿的免疫力。

Objective To explore the efficacy of enhancing immunity of Fuluyin for children with frequent infections. Methods From June 2012 to July 2013, total of 108 cases with recurrent respiratory tract infection in our hospital were divided into treatment group and control group according to the stratified randomization method, each group with 54 cases. The patients in control group were given conventional antiinfection treatment methods for treatment; while the patients in treatment group were given Fuluyin on the base of control group treatment program. The repeated respiratory infection preventive effect and adverse drug reactions of the patients of the both groups were detected before and after treatment, respectively.Results There was no statistical difference significance in immunoglobulin G（Ig G）, immunoglobulin A（IgA）, immunoglobulin M（IgM）, C-reactive protein（CRP） and blood cell sedimentation rate（ESR） of patients in the two groups（P all〉 0.05）. The levels of CRP and ESR, and temperature of treatment group were significantly lower than that in the control group one week after treatment, with significant differences（P all 〈0.05）. The levels of Ig G, Ig A and Ig M in the treatment groups were（10.42 ± 3.87） g/L,（1.96 ± 0.78） g/L and（1.15 ± 0.57） g/L, respectively, significantly higher than that in the control group which were（8.13 ± 3.46） g/L,（1.27 ± 0.53） g/L and（0.82 ± 0.46） g/L at two months after the treatment, with significant differences（P all〈 0.05）. The patients of chills and wheezing of treatment group was significantly lower than the control group（P all 〈0.05）. There was no significant difference on the numbers of patients with adverse reactions such as headache, nausea, diarrhea and skin rashes in the both groups during the treatment（P all 〈0.05）. Conclusions The assisting treatment of Fuluyin for children with recurrent respiratory tract infection could significantly improve the effectiveness of infection control, improve immunity in children.